Duke University Medical Center
research The Garcia-Blanco Lab

Gabor Kemeny
Research Analyst

Gabor Kemeny 1983 - ELTE University; Budapest, Hungary
BA, Biology and Chemistry

1987 - JATE University; Szeged, Hungary
MS, Cell Biology

  Phone: 919.668.0758
Email: gabor.kemeny@duke.edu

Research Interests

Circulating Tumor Cells represent one potential biomarker with both prognostic and predictive abilities in prostate cancer and other tumor types. We identify and characterize measures of epithelial plasticity and stemness in prostate tumors and circulating tumor cells.
Development of a novel method to identify prostate cancer circulating tumor cells (CTCs) based on capture antibodies conjugated to polymersomes (nanotechnology) for a more sensitive and broader- range of PC CTC phenotype detection from men. The improved detection of these cells will allow for improved prognostication but more importantly for the identification of biomarkers and targets for therapy that may prevent or delay metastatic progression.


Bitting RL, Boominathan R, Rao C, Kemeny G, Foulk B, Garcia-Blanco, MA, Connelly M, Armstrong, AJ. Development of a method to isolate circulating tumor cells using mesenchymal-based capture. Methods. 2013 Jul 8.

Armstrong AJ, Shen T, Halabi S, Kemeny G, Bitting RL, Kartcheske P, Embree E, Morris K, Winters C, Jaffe T, Fleming M, George DJ.   A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer. Clin Genitourin Cancer. 2013 Jul 3.

Somarelli JA, Schaeffer D, Bosma R, Bonano VI, Sohn JW, Kemeny G, Ettyreddy A, Garcia-Blanco MA. Fluorescence-based alternative splicing reporters for the study of epithelial plasticity in vivo.   RNA. 2013 Jan;19

Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold CI, Marcom PK, George DJ, Garcia-Blanco MA. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res. 2011 Aug;9:997-1007.